Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kraal, K
Right arrow Articles by Ball, L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kraal, K
Right arrow Articles by Ball, L
Haematologica, Vol 90, Issue Suppl, ECR24-ECR24
Copyright © 2005 by Ferrata Storti Foundation


Case Reports

Optic nerve relapse in a child with common acute lymphoblastic leukemia, treated with systemic anti-CD-20 (rituximab)

K Kraal, N Schalij-Delfos, M van Buchem, M Egeler, and L Ball

Division of Hematology and Oncology, Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands.

We describe a two- year old boy who was diagnosed with pre-B acute lymphoblastic leukemia (ALL). He developed a central nervous system (CNS) relapse with optic nerve involvement. Initially he was treated according to the ALL relapse protocol, including CNS radiotherapy. Despite an initial complete reponse, relapse occurred within six weeks of treatment. The leukemic blast cells were CD-20 positive and he was treated with systemic anti CD-20 therapy (rituximab) with no CNS recurrence over a six-month period. He died due to a CD-20 negative bone marrow relapse. This case illustrates a potential role for rituximab in pediatric CD-20 positive malignancies.





HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2005 by the Ferrata Storti Foundation.